Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

11.71 -0.07 (-0.59%)

Delayed Quote Updated: 11:27 AM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Monday Markets News ↗

March 28, 2022

Japanese Takeda TAK shares failed to thrive after its edema prevention drug was approved.

Via Talk Markets

FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant ↗

March 28, 2022

Via Benzinga

Drug makers, Scientists Working For Long COVID Treatments: Reuters ↗

March 25, 2022

Researchers and drugmakers, including those who have launched antiviral pills and monoclonal antibodies for COVID-19, are having early discussions about targeting Long COVID,

Via Benzinga

Up On Bad News ↗

March 22, 2022

Despite the plane crash in China, Boeing's stock is up today.

Via Talk Markets

Stocks That Hit 52-Week Lows On Wednesday ↗

February 23, 2022

On Wednesday, 348 companies hit new 52-week lows. Significant Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was...

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

March 28, 2022

On Monday, 147 stocks hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was...

Via Benzinga

64 Biggest Movers From Friday ↗

March 28, 2022

Gainers Clever Leaves Holdings Inc. (NASDAQ: CLVR) shares surged 143% to settle at $3.84 on Friday after the company reported better-than-expected Q4 sales results and reaffirmed...

Via Benzinga

World Markets News For Friday ↗

March 18, 2022

Buoyant global markets are closing the week and one good performer, Vir Biotech, today gained an impressive 6.09%.

Via Talk Markets

GSK/Vir Biotech's COVID-19 Antibody Associated With Resistance Mutations, New Research Shows ↗

March 11, 2022

According to new research in Australia, some people have developed sotrovimab-resistant mutations following infusions with the GlaxoSmithKline Plc (NYSE: GSK...

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

March 07, 2022

On Monday, 524 stocks hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Taiwan...

Via Benzinga

Does the FDA Rollback Of Regeneron And Eli Lilly COVID Treatment EUAs Signal A Need To Look Beyond Monoclonal Antibodies? NanoViricides, Inc. Looks To Meet This Need With A New Approach ↗

February 28, 2022

Photo credit: Marcelo Leal and Kate Hliznitsova on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

March 08, 2022

Tuesday's session saw 729 companies set new 52-week lows. Areas of Interest About Today's 52-Week Lows: Amazon.com (NASDAQ:AMZN) was the largest firm on a...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2022 ↗

March 03, 2022

Upgrades For Douglas Emmett Inc (NYSE:DEI), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the fourth quarter, Douglas Emmett had an EPS of $0.48,...

Via Benzinga

AstraZeneca, GSK's COVID-19 Therapies Lose Efficacy Against Omicron's Subvariants ↗

February 25, 2022

The FDA authorized an increased dose in the case of AstraZeneca Plc's (NASDAQ: AZN) pre-exposure prophylaxis drug Evusheld (tixagevimab and cilgavimab)....

Via Benzinga

Recap: Vir Biotechnology Q4 Earnings ↗

February 24, 2022

Vir Biotechnology (NASDAQ:VIR) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

February 28, 2022

On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) was the largest firm on a market cap basis to set a...

Via Benzinga

The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗

February 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...

Via Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

World Markets News For Thursday ↗

February 17, 2022

Ericsson stock lost another 5.27% today in US markets.

Via Talk Markets

Give peace a chance ↗

February 15, 2022

Israeli fabless semiconductor maker Tower was bought by Intel for $5.4 bn today.

Via Talk Markets

Preprint Suggests, Vir-GSK's COVID-19 Antibody Can Evade Omicron Sub-Variant ↗

February 10, 2022

In January, amid the omicron surge, WHO's expert panel recommended GlaxoSmithKline Plc (NYSE

Via Benzinga

Inflation inflating ↗

February 10, 2022

The Fed will be raising interest rates soon and this will chop the appeal of investments in more vulnerable yield plays.

Via Talk Markets

Immunome Shares Seesaw After COVID-19 Antibody Cocktail Works Against Live Omicron Virus ↗

February 08, 2022

Immunome Inc (NASDAQ: IMNM) shares rose before falling after reporting results from testing its experimental three-antibody cocktail

Via Benzinga

The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar ↗

February 08, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Panic reversal ↗

January 26, 2022

Crude oil inventories turned out to be fuller than expected, helping reduce the oil price rise.

Via Talk Markets

WHO Recommends Glaxo, Eli Lilly Drugs For COVID-19 Treatment Amid Omicron Surge ↗

January 14, 2022

An expert panel at the World Health Organization (WHO) recommended the use of treatments developed by Eli Lilly And Co (NYSE: LLY) and GlaxoSmithKline Plc...

Via Benzinga

GSK, Vir Biotech File For Emergency Use Nod For Intramuscular Sotrovimab For COVID-19 ↗

January 13, 2022

GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have applied to the FDA to include intramuscular (IM) administration to sotrovimab...

Via Benzinga

Vir Biotechnology Expands Partnership With Bill & Melinda Gates Foundation, Launches New Antibody Research Initiative Aimed At A Functional Cure For HIV And Prevention Of Malaria; Foundation Has Committed $40M Equity Investment And $10M Grant ↗

January 13, 2022

Vir Biotechnology, Inc. (NASDAQ: VIR) today announced an expansion of its partnership with the Bill & Melinda Gates Foundation to include the advancement of innovative...

Via Benzinga

Adagio's COVID-19 Antibody Has Neutralizing Activity Comparable To Other Antibodies ↗

January 13, 2022

Adagio Therapeutics Inc (NASDAQ: ADGI) shares gain during the premarket session after recent findings showing that ADG20 has neutralization activity against the omicron...

Via Benzinga

20 Stocks Moving in Thursday's Pre-Market Session ↗

January 13, 2022

Gainers BTCS Inc. (NASDAQ: BTCS) rose 41% to $9.45 in pre-market trading after jumping 19% on Wednesday. Adagio Therapeutics, Inc. (NASDAQ: ADGI) rose 22.8% to $7.16 in pre-...

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.